IDO-IN-7
IDO-IN-7 Basic information
- Product Name:
- IDO-IN-7
- Synonyms:
-
- IDO-IN-7
- Navoximod
- IDO-IN-7(Navoximod)
- Navoximod (NLG919)
- 5H-Imidazo[5,1-a]isoindole-5-ethanol, 6-fluoro-α-(trans-4-hydroxycyclohexyl)-, (αR,5S)-
- Reaxys ID: 22999399
- GDC-0917;CUDC427;CUDC 427;GDC0917;GDC 0917
- Navoximod (Synonyms: GDC-0919
- CAS:
- 1402837-78-8
- MF:
- C18H21FN2O2
- MW:
- 316.38
- Product Categories:
-
- api
- Mol File:
- 1402837-78-8.mol
IDO-IN-7 Chemical Properties
- Boiling point:
- 555.4±35.0 °C(Predicted)
- Density
- 1.42±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO:100.0(Max Conc. mg/mL);316.09(Max Conc. mM)
- pka
- 14.66±0.20(Predicted)
- form
- Solid
- color
- White to light yellow
- InChI
- InChI=1/C18H21FN2O2/c19-14-3-1-2-13-16-9-20-10-21(16)15(18(13)14)8-17(23)11-4-6-12(22)7-5-11/h1-3,9-12,15,17,22-23H,4-8H2/t11-,12-,15-,17+/s3
- InChIKey
- YGACXVRLDHEXKY-YYJRJVKZNA-N
- SMILES
- C([C@@H]1N2C=NC=C2C2=CC=CC(F)=C12)[C@H]([C@]1([H])CC[C@@H](O)CC1)O |&1:1,14,15,19,r|
IDO-IN-7 Usage And Synthesis
Uses
Navoximod (GDC-0919; NLG-?919) is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.
in vivo
VNavoximod (NLG919) is orally bioavailable (F>70%); and has a favorable pharmacokinetic and toxicity profile. In mice, a single oral administration of Navoximod reduces the concentration of plasma and tissue Kyn by ~50%. In vivo, in mice bearing large established B16F10 tumors, administration of Navoximod markedly enhances the anti-tumor responses of na?ve, resting pmel-1 cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA. In this stringent established-tumor model, Navoximod plus pmel-1/vaccine produce a dramatic collapse of tumor size within 4 days of vaccination (~95% reduction in tumor volume compare to control animals receiving pmel-1/vaccine alone without Navoximod)[1]. When combined with NSC 362856 (TMZ)+radiation therapy (RT), both Navoximod and D-1MT (Indoximod) enhance survival relative to mice treated with TMZ+RT alone[2].
IC 50
IDO: 7 nM (Ki); IDO: 75 nM (EC50)
References
[1] Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.
[2] Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21. DOI:10.1186/2051-1426-2-21
[3] Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443. DOI:10.1038/ncomms13443
IDO-IN-7Supplier
- Tel
- 18062115889
- 405368533@qq.com
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- 021-58955995
- sales@medchemexpress.cn
- Tel
- 021-52996696，15000506266 15000506266
- Tel
- 021-61350663 13052117465
- sales@zehanbiopharma.com
IDO-IN-7(1402837-78-8)Related Product Information
- PURVALANOL A
- Testolactone
- GDC-0077
- AGI6780
- CC0651
- 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine
- UNC 0631
- XL 228
- N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea
- Β-LAPACHONE
- IDO-IN-1
- indoleaMine-2,3-dioxygenase inhibitor INCB024360
- NLG919
- 3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dione
- 1-METHYL-D-TRYPTOPHAN
- IDO-IN-3
- IDO-IN-4
- 8-Nitrotryptanthrin